A phase II, open, randomised study to assess the efficacy and safety of AZD6244 vs. capecitabine (Xeloda[Rm]) in patients with advanced or metastatic pancreatic cancer, who have failed first line gemcitabine therapy

Trial Profile

A phase II, open, randomised study to assess the efficacy and safety of AZD6244 vs. capecitabine (Xeloda[Rm]) in patients with advanced or metastatic pancreatic cancer, who have failed first line gemcitabine therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2013

At a glance

  • Drugs Capecitabine; Selumetinib
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 May 2009 Actual end date (1 Oct 2008) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Feb 2008 Status changed from recruiting to in progress according to NCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top